Team:UCL/Project

From 2013.igem.org

(Difference between revisions)
 
(24 intermediate revisions not shown)
Line 47: Line 47:
<div class="col_left" style="width:100%;">
<div class="col_left" style="width:100%;">
-
<p class="major_title">Genetic Engineering</p>
+
<p class="major_title">IGEM: INTELLIGENTLY GENETICALLY ENGINEERED MICROGLIA</p>
-
<p class="minor_title">Ethical Questions</p>
+
<p class="minor_title">Synthetic Biology Fights Alzheimer's Disease</p>
<p class="abstract_text" style="color:#404040;">
<p class="abstract_text" style="color:#404040;">
-
This year, the UCL iGEM team is taking a radical new step with synthetic biology. We intend to explore the potential application genetic engineering techniques on the brain, because it is the site of some of the most subtle, and many of the most devastating diseases known to medicine. We have devised a genetic circuit for transfecting into a novel chassis for iGEM that is rarely engineered in research - microglial cells, the resident immune cells of the brain. The circuit aims to boost the ability of the microglial cells to break down senile plaques, which are associated with the onset and progression of Alzheimer’s Disease, as well as to protect neurons under threat from these plaques and from inflammation. Alzheimer’s Disease is a neurodegenerative disease that is characterised by the loss of recent memory and intellectual functions. Late stages of the disease often see patients bedridden, mute and incontinent. It is a horrific condition for which a genetic engineering response is both pertinent and somewhat disconcerting. Therefore, we also delve into the neuroethics of the potential progression of synthetic biology in neuroscience.
+
This year, the UCL iGEM team is taking a radical new step with synthetic biology. We intend to explore the potential application genetic engineering techniques on the brain, because it is the site of some of the most subtle, and many of the most devastating medical conditions. Alzheimer’s Disease is a neurodegenerative disease characterised by the loss of recent memory and intellectual functions. We have devised a genetic circuit for transfection into microglia, a novel chassis in which standard assembly has never been used, to boost their ability to break down senile plaques, which are associated with Alzheimer’s disease, as well as to support and protect endangered neurons from microglia-mediated neuroinflammation.
<br><br>
<br><br>
</p>
</p>
Line 68: Line 68:
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration" style="background-image:url('#');">
+
<div class="col_illustration">
-
</div>
+
<a href="https://static.igem.org/mediawiki/2013/1/1a/CircuitOverviewMicroglia.gif" data-lightbox="image-1" title="Genetic Circuit Overview in Microglia UCL iGEM 2013">
 +
<img src="https://static.igem.org/mediawiki/2013/1/1a/CircuitOverviewMicroglia.gif">
 +
</a>
 +
</div>
<div class="col_abstract">
<div class="col_abstract">
-
<a href="#">
+
<a href="https://2013.igem.org/Team:UCL/Project/Circuit">
<p class="abstract_title">Circuit Overview</p>
<p class="abstract_title">Circuit Overview</p>
<p class="abstract_text">
<p class="abstract_text">
-
Our genetic circuit aims primarily to remove amyloid plaques in the brain, which are strongly associated with Alzheimer’s disease. Our circuit focuses on three core parts; firstly, a promoter which responds to oxidative stress - this can be used as a proxy to detect plaques. Secondly, a plaque-degrading protease, which will be secreted in response to oxidative stress, and thirdly, a chemoattractant, also secreted in response to oxidative stress, which will draw more microglia towards the plaque. We have also developed our own selectable marker, which we can use to select for transformations of mammalian cells.
+
Our genetic circuit aims primarily to remove amyloid plaques in the brain, which are associated with Alzheimer’s disease, prevent neuroinflammation and support neurons.
</p>
</p>
</a>
</a>
Line 88: Line 91:
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration" style="background-image:url('#');">
+
<div class="col_illustration">
-
</div>
+
<a href="https://static.igem.org/mediawiki/2013/1/18/Detectionucligem.gif" data-lightbox="image-1" title="Oxidative Stress Promoter for Plaque Detection UCL iGEM 2013">
 +
<img src="https://static.igem.org/mediawiki/2013/1/18/Detectionucligem.gif">
 +
</a>
 +
</div>
<div class="col_abstract">
<div class="col_abstract">
-
<a href="https://2013.igem.org/Team:UCL/Practice/Creative">
+
<a href="https://2013.igem.org/Team:UCL/Project/Detection">
<p class="abstract_title">Detection</p>
<p class="abstract_title">Detection</p>
<p class="abstract_text">
<p class="abstract_text">
-
Senile plaques increase the rate of production of reactive oxygen species which is damaging to brain cells. We capitalise on this, by creating a promoter sensitive to oxidative stress, in order to initiate the production of other circuit parts.
+
Senile plaques increase the rate of production of reactive oxygen species that are damaging to brain cells. We developed an oxidative stress promoter, in order to initiate the production of other circuit parts.
</p>
</p>
Line 109: Line 115:
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration" style="background-image:url('#');">
+
<div class="col_illustration">
-
</div>
+
<a href="https://static.igem.org/mediawiki/2013/5/57/Chemotaxisucligem.gif" data-lightbox="image-1" title="Chemotaxis in Microglia UCL iGEM 2013">
 +
<img src="https://static.igem.org/mediawiki/2013/5/57/Chemotaxisucligem.gif">
 +
</a>
 +
</div>
<div class="col_abstract">
<div class="col_abstract">
-
<a href="https://2013.igem.org/Team:UCL/Practice/Neuroethics">
+
<a href="https://2013.igem.org/Team:UCL/Project/Chemotaxis">
-
<p class="abstract_title">Chemotaxis</p>
+
<p class="abstract_title">Insertion</p>
<p class="abstract_text">
<p class="abstract_text">
-
Microglia readily migrate towards plaques in vivo, but to see if we could increase migration to plaques, we produced a chemoattractant to help them converge.
+
The brain is an immune privileged organ and the security of the blood brain barrier makes it difficult to get all but the smallest molecules, such as glucose, from the rest of the body into the brain. This makes inserting our genetic circuit into the brain a trickier task than in most synthetic biomedical projects. Here we examine some plausible methods.
</p>
</p>
Line 130: Line 139:
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration" style="background-image:url('#');">
+
<div class="col_illustration">
-
</div>
+
<a href="https://static.igem.org/mediawiki/2013/4/46/Degradationucligem.gif" data-lightbox="image-1" title="Beta-Amyloid degradation by MMP-9 UCL iGEM 2013">
 +
<img src="https://static.igem.org/mediawiki/2013/4/46/Degradationucligem.gif">
 +
</a>
 +
</div>
<div class="col_abstract">
<div class="col_abstract">
-
<a href="https://2013.igem.org/Team:UCL/Practice/Documentary">
+
<a href="https://2013.igem.org/Team:UCL/Project/Degradation">
<p class="abstract_title">Degradation</p>
<p class="abstract_title">Degradation</p>
<p class="abstract_text">
<p class="abstract_text">
-
We expressed and characterised MMP-9 in several chassis. MMP-9 is a matrix metalloproteinase that is capable of degrading amyloid. By increasing its expression in de-activated microglia, we hope to be able to reduce amyloid burden in Alzheimer’s disease.
+
We expressed and characterised a matrix metalloproteinase that is capable of degrading amyloid. By increasing its expression in de-activated microglia, we hope to reduce amyloid burden in Alzheimer’s disease.
</p>
</p>
</a>
</a>
Line 150: Line 162:
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration" style="background-image:url('#');">
+
<div class="col_illustration">
-
</div>
+
<a href="https://static.igem.org/mediawiki/2013/8/8a/Selectablemarkerzeocin.gif" data-lightbox="image-1" title="Selectable Marker, Zeocin UCL iGEM 2013">
 +
<img src="https://static.igem.org/mediawiki/2013/8/8a/Selectablemarkerzeocin.gif">
 +
</a>
 +
</div>
<div class="col_abstract">
<div class="col_abstract">
-
<a href="https://2013.igem.org/Team:UCL/Practice/Debate">
+
<a href="https://2013.igem.org/Team:UCL/Project/Marker">
<p class="abstract_title">Selectable Marker</p>
<p class="abstract_title">Selectable Marker</p>
<p class="abstract_text">
<p class="abstract_text">
-
We used resistance to zeocin, a cell killing glycoprotein, to act as a selectable marker transformation/transfection in all our chassis, E.coli, HeLa and microglia.
+
We used resistance to zeocin, a cell killing glycoprotein, to act as a selectable marker for transformation/transfection in our chassis; E.coli, HeLa and microglia.
 +
 
 +
The biobrick that we made encoding zeocin resistance is a step forward for selectable markers in iGEM - the first one of its kind tailored for mammalian expression systems.  
</p>
</p>
Line 171: Line 188:
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration" style="background-image:url('#');">
+
<div class="col_illustration">
-
</div>
+
<a href="https://static.igem.org/mediawiki/2013/e/e1/ChassisUCLigem2013.gif" data-lightbox="image-1" title="Chassis: E.coli, HeLa and Microglia UCL iGEM 2013">
 +
<img src="https://static.igem.org/mediawiki/2013/e/e1/ChassisUCLigem2013.gif">
 +
</a>
 +
</div>
<div class="col_abstract">
<div class="col_abstract">
-
<a href="https://2013.igem.org/Team:UCL/Practice/Report">
+
<a href="https://2013.igem.org/Team:UCL/Project/Chassis">
<p class="abstract_title">Chassis</p>
<p class="abstract_title">Chassis</p>
<p class="abstract_text">
<p class="abstract_text">
-
We conducted our experiments in three chassis, creating recombinant plasmids in E.coli and expressing them in HeLa, and finally, the much harder to transfect primary and immortalised human microglia lines.
+
We conducted our experiments in three chassis, creating recombinant plasmids in E.coli before expressing them in HeLa and finally primary and immortalised human microglia lines. Human brain cells have not been seen before in an iGEM project, with experiments in microglia coming as son as they arrive!
</p>
</p>
</a>
</a>
Line 191: Line 211:
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration" style="background-image:url('#');">
+
<div class="col_illustration">
-
</div>
+
<a href="https://static.igem.org/mediawiki/2013/d/da/PartsUCligem2013.gif" data-lightbox="image-1" title="BioBrick Parts Submitted to the Registry UCL iGEM 2013">
 +
<img src="https://static.igem.org/mediawiki/2013/d/da/PartsUCligem2013.gif">
 +
</a>
 +
</div>
<div class="col_abstract">
<div class="col_abstract">
-
<a href="https://2013.igem.org/Team:UCL/Practice/Survey">
+
<a href="https://2013.igem.org/Team:UCL/Project/Parts">
<p class="abstract_title">Parts</p>
<p class="abstract_title">Parts</p>
<p class="abstract_text">
<p class="abstract_text">
-
We submitted X parts to the registry, LIST GENE NAMES and improved X, LIST GENE NAMES. To be filled in later
+
We submitted two parts to the registry; a new eukaryotic and prokaryotic selectable marker, and the protease, MMP-9.
Line 204: Line 227:
</a>
</a>
</div>
</div>
 +
 +
</div>
 +
 +
 +
<div class="gap">
 +
</div>
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration" style="background-image:url('#');">
+
<div class="col_illustration">
-
</div>
+
<a href="https://static.igem.org/mediawiki/2013/8/8e/FuturedevelopmentsUCLigem2013.gif" data-lightbox="image-1" title="Looking beyond our summer lab work UCL iGEM 2013">
 +
<img src="https://static.igem.org/mediawiki/2013/8/8e/FuturedevelopmentsUCLigem2013.gif">
 +
</a>
 +
</div>
<div class="col_abstract">
<div class="col_abstract">
-
<a href="https://2013.igem.org/Team:UCL/Practice/TED">
+
<a href="https://2013.igem.org/Team:UCL/Project/Developments">
<p class="abstract_title">Future Developments</p>
<p class="abstract_title">Future Developments</p>
<p class="abstract_text">
<p class="abstract_text">
-
Our circuit design is far from finished; given sufficient time, we would have included several other important components.
+
Our circuit design is far from finished; given sufficient time in the lab, we would have included several other important components, including the de-activating agent VIP and the support factor BDNF.
</p>
</p>
</a>
</a>
</div>
</div>
-
 
+
-
+
</div>
</div>
Line 227: Line 259:
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration" style="background-image:url('#');">
+
<div class="col_illustration">
-
</div>
+
<a href="https://static.igem.org/mediawiki/2013/b/b4/ExperimentsUCLigem2013.gif" data-lightbox="image-1" title="Experiments UCL iGEM 2013">
 +
<img src="https://static.igem.org/mediawiki/2013/b/b4/ExperimentsUCLigem2013.gif">
 +
</a>
 +
</div>
<div class="col_abstract">
<div class="col_abstract">
-
<a href="https://2013.igem.org/Team:UCL/Practice/TED">
+
<a href="https://2013.igem.org/Team:UCL/Project/Experiments">
<p class="abstract_title">Experiments</p>
<p class="abstract_title">Experiments</p>
<p class="abstract_text">
<p class="abstract_text">
-
Fill in later.
+
Here we explain the wet-lab experiments that built our project. All of these experiments built the foundation of our project, allowing us to generate, test and subsequently submit biobricks to the registry.
-
</p>
+
 
 +
This section includes experiments for both bacterial and mammalian lab that have been performed before the Lyon jamboree!
 +
</p>
</a>
</a>
</div>
</div>
Line 247: Line 284:
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration" style="background-image:url('#');">
+
<div class="col_illustration">
-
</div>
+
<a href="https://static.igem.org/mediawiki/2013/4/4c/Labook_pic.jpg" data-lightbox="image-1" title="Protocols UCL iGEM 2013">
 +
<img src="https://static.igem.org/mediawiki/2013/4/4c/Labook_pic.jpg">
 +
</a>
 +
</div>
<div class="col_abstract">
<div class="col_abstract">
-
<a href="https://2013.igem.org/Team:UCL/Practice/TED">
+
<a href="https://2013.igem.org/Team:UCL/Project/Protocols">
<p class="abstract_title">Lab Protocols</p>
<p class="abstract_title">Lab Protocols</p>
<p class="abstract_text">
<p class="abstract_text">
-
Fill in later.
+
You cannot plan an experiment without the procedure. Here we have stored all of the protocols that were used in order to make out wet lab work possible.
 +
 
 +
This section includes protocols for both bacterial and mammalian lab experiments that have been performed before the Lyon jamboree!
</p>
</p>
</a>
</a>
</div>
</div>
 +
 +
 +
</div>
<div class="gap">
<div class="gap">
Line 264: Line 309:
<div class="row_small">
<div class="row_small">
-
<div class="col_illustration" style="background-image:url('#');">
+
<div class="col_illustration">
-
</div>
+
<a href="https://static.igem.org/mediawiki/2013/b/b6/Silent_safety.jpg" data-lightbox="image-1" title="Safety First UCL iGEM 2013">
 +
<img src="https://static.igem.org/mediawiki/2013/b/b6/Silent_safety.jpg">
 +
</a>
 +
</div>
<div class="col_abstract">
<div class="col_abstract">
-
<a href="https://2013.igem.org/Team:UCL/Practice/TED">
+
<a href="https://2013.igem.org/Team:UCL/Project/Safety">
<p class="abstract_title">Safety</p>
<p class="abstract_title">Safety</p>
<p class="abstract_text">
<p class="abstract_text">
-
For experimental procedures, it is essential that both the personnel and the experimental products are as safe as possible to avoid harm. Risk may be minimised by following safety procedures for any likely situations that may occur in the laboratory environment.
+
It is essential that both personnel and experimental products are as safe as possible to avoid harm. Risk may be minimised by following safety procedures for any plausible dangerous situation that may occur in the laboratory.
</p>
</p>
</a>
</a>

Latest revision as of 03:22, 5 October 2013

IGEM: INTELLIGENTLY GENETICALLY ENGINEERED MICROGLIA

Synthetic Biology Fights Alzheimer's Disease

This year, the UCL iGEM team is taking a radical new step with synthetic biology. We intend to explore the potential application genetic engineering techniques on the brain, because it is the site of some of the most subtle, and many of the most devastating medical conditions. Alzheimer’s Disease is a neurodegenerative disease characterised by the loss of recent memory and intellectual functions. We have devised a genetic circuit for transfection into microglia, a novel chassis in which standard assembly has never been used, to boost their ability to break down senile plaques, which are associated with Alzheimer’s disease, as well as to support and protect endangered neurons from microglia-mediated neuroinflammation.

Click the abstracts below to read more.